Macitentan (Opsumit) for the indication pulmonary arterial hypertension WHO class II to III

The WAR has approved a pharmacotherapeutic report for the medicine macitentan (Opsumit®; an endothelin-1-receptor antagonist). In determining its therapeutic value, comparison was made with bosentan (also an endothelin-1-receptor antagonist).
They reached the following conclusion:

• the therapeutic value of macitentan, as monotherapy, or in combination (with other drugs for treating PAH), for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, is comparable to that of bosentan. 

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.